comparemela.com
Home
Live Updates
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD - Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI) : comparemela.com
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD - Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI)
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub
Related Keywords
Canada
,
Canadian
,
Rick Doblin
,
Protik Basu
,
Beckley Psytech
,
Joe Samberg
,
Cybin Inc
,
Multidisciplinary Association For Psychedelic Studies
,
Public Benefit Corporation
,
Multidisciplinary Association
,
Psychedelic Studies
,
Benefit Corporation
,
New Drug Application
,
Psychedelics Researchers
,
Industry Leaders Weigh In On Groundbreaking
,
comparemela.com © 2020. All Rights Reserved.